Methods and compositions for inhibition of nuclear factor kappaB
US8722613B2 · kind B2 · utility
0Cited by
1References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 27, 2004 |
| Grant date | May 13, 2014 |
| Priority date | — |
| Expiry date | Jul 29, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A series of p105-based NF-κB super repressors, designated p-105(sr), have been designed. The p105(sr), no longer generates p50 and undergoes signal-induced degradation, effectively inhibiting all NF-κB activities. Additionally, p105(sr) significantly enhances tumor necrosis factor alpha (TNF-α)-mediated killing of MT1/2 skin papilloma cells when p50 homodimer activity is elevated. p105(sr) is an effective NF-κB super repressor with a broader range than other currently available IkBα super repressors. The novel repressor can be used in cells where a noncanical NF-κB activity is dominant or multiple NF-κB activities are activated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.